汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作

智通财经01-09

智通财经APP讯，汇宇制药(688553.SH)发布公告，公司全资子公司汇宇海玥自主研发的I类创新药HYP-6589片(项目研发代号为“HY-0006”)是一种高选择性SOS1小分子抑制剂。奥希替尼(商品名：泰瑞沙)是阿斯利康自主研发的一种第三代口服表皮生长因子受体酪氨酸激酶抑制剂，已于中国获批上市，适用于特定类型非小细胞肺癌的治疗。近日公司全资子公司汇宇海玥与阿斯利康签署了《临床试验合作协议》，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2602323004?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-09 16:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602323004","market":"fut","top_or_hot":-1,"title":"汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作","media":"智通财经","content":"<div>\n<p>智通财经APP讯，汇宇制药(688553.SH)发布公告，公司全资子公司汇宇海玥自主研发的I类创新药HYP-6589片(项目研发代号为“HY-0006”)是一种高选择性SOS1小分子抑制剂。奥希替尼(商品名：泰瑞沙)是阿斯利康自主研发的一种第三代口服表皮生长因子受体酪氨酸激酶抑制剂，已于中国获批上市，适用于特定类型非小细胞肺癌的治疗。近日公司全资子公司汇宇海玥与阿斯利康签署了《临床试验合作协议》，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1390897.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 16:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1390897.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，汇宇制药(688553.SH)发布公告，公司全资子公司汇宇海玥自主研发的I类创新药HYP-6589片(项目研发代号为“HY-0006”)是一种高选择性SOS1小分子抑制剂。奥希替尼(商品名：泰瑞沙)是阿斯利康自主研发的一种第三代口服表皮生长因子受体酪氨酸激酶抑制剂，已于中国获批上市，适用于特定类型非小细胞肺癌的治疗。近日公司全资子公司汇宇海玥与阿斯利康签署了《临床试验合作协议》，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1390897.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2462157665.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1390897.html","article_id":"2602323004","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602323004","pubTimestamp":1767947265,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，汇宇制药 发布公告，公司全资子公司汇宇海玥自主研发的I类创新药HYP-6589片是一种高选择性SOS1小分子抑制剂。近日公司全资子公司汇宇海玥与阿斯利康签署了《临床试验合作协议》，就HYP-6589片与奥希替尼临床联合用药研究展开合作。公司与阿斯利康达成临床研究合作，合作双方共同探索公司自主研发的化学药I类创新药HYP-6589片与阿斯利康奥希替尼联合治疗特定类型非小细胞肺癌的疗法。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688553":"汇宇制药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4588":"碎股","BK0239":"医药制造","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","BK4568":"美国抗疫概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","AZN":"阿斯利康"},"translate_title":"Huiyu Pharmaceutical (688553. SH) subsidiary and AstraZeneca reached clinical research cooperation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688553":1.5,"AZN":1.5},"content_text":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司全资子公司汇宇海玥自主研发的I类创新药HYP-6589片(项目研发代号为“HY-0006”)是一种高选择性SOS1小分子抑制剂。奥希替尼(商品名：泰瑞沙)是阿斯利康自主研发的一种第三代口服表皮生长因子受体酪氨酸激酶抑制剂，已于中国获批上市，适用于特定类型非小细胞肺癌的治疗。近日公司全资子公司汇宇海玥与阿斯利康签署了《临床试验合作协议》，就HYP-6589片与奥希替尼临床联合用药研究展开合作。公司与阿斯利康达成临床研究合作，合作双方共同探索公司自主研发的化学药I类创新药HYP-6589片与阿斯利康奥希替尼联合治疗特定类型非小细胞肺癌的疗法。合作双方将开展HYP-6589与奥希替尼联合治疗特定类型非小细胞肺癌的临床试验研究，用以评估HYP-6589单药和联合奥希替尼的安全性、耐受性、药代动力学和有效性。公司坚持全面拥抱创新，加速抗肿瘤治疗领域生物创新药和小分子创新药的研发布局，现有14条I类创新药管线，涉及多特异性抗体、抗体偶联药物等前沿技术路线，其中5条I类创新药管线进入临床研究。本次公司与阿斯利康的临床研究合作有利于加快公司创新药临床试验进程，提升研发效率;有利于扩大公司新药研发能力和范围，一定程度上节约了公司新药临床试验的时间和成本，保障项目的顺利进行。此次事项预计不会对公司的财务状况和经营成果产生重大影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602323004","isCrawlerRequest":true}